Skip to main content

Peer Review reports

From: The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials

Original Submission
27 Apr 2023 Submitted Original manuscript
20 May 2023 Reviewed Reviewer Report
29 May 2023 Reviewed Reviewer Report
14 Jun 2023 Reviewed Reviewer Report
10 Jul 2023 Author responded Author comments - Saeid Safiri
Resubmission - Version 2
10 Jul 2023 Submitted Manuscript version 2
22 Jul 2023 Reviewed Reviewer Report
14 Aug 2023 Author responded Author comments - Saeid Safiri
Resubmission - Version 3
14 Aug 2023 Submitted Manuscript version 3
23 Aug 2023 Reviewed Reviewer Report
14 Sep 2023 Reviewed Reviewer Report
4 Nov 2023 Author responded Author comments - Saeid Safiri
Resubmission - Version 4
4 Nov 2023 Submitted Manuscript version 4
Publishing
7 Nov 2023 Editorially accepted
8 Dec 2023 Article published 10.1186/s12890-023-02755-3

You can find further information about peer review here.

Back to article page